One of the pioneers harnessing the CRISPR/Cas-9 to develop human therapeutics, Switzerland-based CRISPR Therapeutics AG is confident its lead program in sickle cell disease and beta-thalassemia therapies will generate a product launch by 2022, and that the ongoing global patent wrangling over the technology won't get in the way of that objective.
CRISPR Therapeutics uses its proprietary CRISPR/Cas9 gene-editing platform to develop gene-based medicines for curing serious diseases at the molecular level related to the hematopoietic system, the liver, and the musculoskeletal...
